AlzeCure Pharma (ALZCUR) Investor update summary

Strategic partnerships and collaborations

• Secured two transformative out-licensing and collaboration deals with Eli Lilly and QuantumCell, totaling $3.2 billion in deal value, excluding royalties.

• Entered collaboration and outlicensing agreements with Eli Lilly for the Alzstatin platform targeting Alzheimer's disease.

• Signed a collaboration agreement with QuantumCell ApS for the NeuroRestore platform.

• Received $22 million in upfront payments and completed a SEK 30 million rights issue, strengthening the cash position.

• Ongoing collaborations with Eli Lilly and QuantumCell involve active tech transfer and program initiation.

Company focus and development

• Business model centers on identifying targets, developing small molecules in-house, and out-licensing after clinical development.

• Focuses on developing small-molecule drug candidates for CNS diseases, especially Alzheimer's and pain.

• Advances multiple drug candidates in parallel across three platforms: NeuroRestore, Alzstatin, and Painless.

Pipeline and therapeutic focus

• Focused on Alzheimer's and pain, addressing large and growing unmet medical needs.

• Alzstatin platform, a gamma-secretase modulator for Alzheimer's, out-licensed to Eli Lilly.

• NeuroRestore platform, targeting learning, memory, and depression, out-licensed to QuantumCell.

• Painless platform includes ACD137 for osteoarthritis and ACD440 for neuropathic pain and erythromelalgia.